1.
SCORE Study report #11: incidences of neovascular events in eyes with retinal vein occlusion.
Chan Clement K, Ip Michael S, Vanveldhuisen Paul C, Oden Neal L, Scott Ingrid U, Tolentino Michael J et al.
OphthalmologyJul 201159 citationsRandomized Controlled Trial
The SCORE study found triamcinolone didn't reduce neovascular events in RVO. Neovascularization risk significantly increased with greater retinal nonperfusion, especially in BRVO, highlighting nonperfusion as a key risk factor.